KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Research & Development (2016 - 2025)

Historic Research & Development for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$2.3 billion.

  • Gsk's Research & Development fell 2019.66% to -$2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.0 billion, marking a year-over-year decrease of 1302.75%. This contributed to the annual value of $8.2 billion for FY2024, which is 570.95% up from last year.
  • As of Q3 2025, Gsk's Research & Development stood at -$2.3 billion, which was down 2019.66% from -$2.7 billion recorded in Q2 2025.
  • Gsk's Research & Development's 5-year high stood at -$1.5 billion during Q1 2021, with a 5-year trough of -$8.2 billion in Q4 2024.
  • Over the past 5 years, Gsk's median Research & Development value was -$1.9 billion (recorded in 2021), while the average stood at -$2.7 billion.
  • Within the past 5 years, the most significant YoY rise in Gsk's Research & Development was 1873.64% (2022), while the steepest drop was 24703.54% (2022).
  • Gsk's Research & Development (Quarter) stood at -$1.9 billion in 2021, then tumbled by 247.04% to -$6.4 billion in 2022, then fell by 19.99% to -$7.7 billion in 2023, then dropped by 6.37% to -$8.2 billion in 2024, then surged by 72.27% to -$2.3 billion in 2025.
  • Its last three reported values are -$2.3 billion in Q3 2025, -$2.7 billion for Q2 2025, and -$1.8 billion during Q1 2025.